CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
ALXN1840drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05641311
NCT05641311Phase 1Completed
CompareCT.gov

An Open-Label, Two-Single Dose, Two-Period, Parallel Group Study to Assess the Pharmacokinetics and Safety of ALXN1840 in Healthy Adult Japanese and Non-Japanese Subjects

Alexion Pharmaceuticals, Inc.·interventional·Posted Dec 7, 2022·Updated Nov 7, 2023

In Brief

A Phase 1 clinical trial evaluating ALXN1840 for Wilson Disease. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The main purpose of the study is to confirm how long ALXN1840 stays in the body of Japanese and non-Japanese healthy participants (that is, pharmacokinetic \[PK\] profile).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWilson Disease
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedDec 7, 2022
Enrollment StartFeb 20, 2019
Primary CompletionMay 2, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.6 years ago

Interventions

ALXN1840drug

Tablet for oral use.